FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306971427> ?p ?o ?g. }

• W4306971427 endingPage "101111" @default.
• W4306971427 startingPage "101111" @default.
• W4306971427 abstract "PurposeOur purpose was to report the results of a phase II trial of patients with breast cancer treated with hypofractionated whole breast radiation therapy (RT) before breast-conserving surgery (BCS).Methods and MaterialsBetween 2019 and 2020, patients with cT0-T2, N0, M0 breast cancer were enrolled. Patients were treated with hypofractionated whole breast RT, 25 Gy in 5 fractions, 4 to 8 weeks before BCS. Pathologic assessment was performed using the residual cancer burden (RCB). Toxicities were assessed according to Common Terminology Criteria for Adverse Events (version 4). Quality of life was assessed with Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events, The Breast Cancer Treatment Outcome Scale, Linear Analogue Self-Assessment, and Patient-Reported Outcomes Measurement Information System.ResultsTwenty-two patients were enrolled. Median follow-up was 7.6 months (range, 0.2-16.8). Seven (32%) and 2 (9%) patients experienced grade 2+ or 3 toxicities, respectively. Overall quality of life Linear Analogue Self-Assessment and Patient-Reported Outcomes Measurement Information System did not change significantly from baseline (P = .21 and P = .72, respectively). There was no clinically significant change (≥1 point) in any of The Breast Cancer Treatment Outcome Scale domains. Only 1 (5%) patient experienced a clinical deterioration that corresponded to a “fair” outcome on the Harvard Cosmesis Scale. At pathologic evaluation, 14 (64%) patients had RCB-0 or RCB-I, including 3 (14%) patients with a pathologic complete response (RCB-0). Eight patients (36%) had RCB-II. No local or distant recurrences have been observed.ConclusionsExtremely hypofractionated whole breast RT before BCS is a feasible approach. There were low rates of toxicities and good cosmesis. Further investigation into this approach with RT before BCS is warranted." @default.
• W4306971427 created "2022-10-22" @default.
• W4306971427 creator A5007891912 @default.
• W4306971427 creator A5014871823 @default.
• W4306971427 creator A5016852500 @default.
• W4306971427 creator A5017336412 @default.
• W4306971427 creator A5020408757 @default.
• W4306971427 creator A5020593703 @default.
• W4306971427 creator A5022657400 @default.
• W4306971427 creator A5031687017 @default.
• W4306971427 creator A5035789115 @default.
• W4306971427 creator A5038061103 @default.
• W4306971427 creator A5042066240 @default.
• W4306971427 creator A5044724288 @default.
• W4306971427 creator A5048944322 @default.
• W4306971427 creator A5050962544 @default.
• W4306971427 creator A5069611083 @default.
• W4306971427 date "2023-01-01" @default.
• W4306971427 modified "2023-09-29" @default.
• W4306971427 title "Pilot/Phase II Trial of Hypofractionated Radiation Therapy to the Whole Breast Alone Before Breast Conserving Surgery" @default.
• W4306971427 cites W1500603626 @default.
• W4306971427 cites W1984254136 @default.
• W4306971427 cites W2010059019 @default.
• W4306971427 cites W2015351481 @default.
• W4306971427 cites W2023494838 @default.
• W4306971427 cites W2067420088 @default.
• W4306971427 cites W2089814647 @default.
• W4306971427 cites W2096145980 @default.
• W4306971427 cites W2096499183 @default.
• W4306971427 cites W2100457375 @default.
• W4306971427 cites W2103608035 @default.
• W4306971427 cites W2153477869 @default.
• W4306971427 cites W2167353413 @default.
• W4306971427 cites W2321697532 @default.
• W4306971427 cites W2555240095 @default.
• W4306971427 cites W2590468337 @default.
• W4306971427 cites W2593021861 @default.
• W4306971427 cites W2740659413 @default.
• W4306971427 cites W2758176523 @default.
• W4306971427 cites W2946453288 @default.
• W4306971427 cites W2991896238 @default.
• W4306971427 cites W2992619229 @default.
• W4306971427 cites W2993667428 @default.
• W4306971427 cites W2999831124 @default.
• W4306971427 cites W3001515809 @default.
• W4306971427 cites W3016251265 @default.
• W4306971427 cites W3022548009 @default.
• W4306971427 cites W3041125947 @default.
• W4306971427 cites W3081515379 @default.
• W4306971427 cites W3086124540 @default.
• W4306971427 cites W3134729812 @default.
• W4306971427 doi "https://doi.org/10.1016/j.adro.2022.101111" @default.
• W4306971427 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36483068" @default.
• W4306971427 hasPublicationYear "2023" @default.
• W4306971427 type Work @default.
• W4306971427 citedByCount "0" @default.
• W4306971427 crossrefType "journal-article" @default.
• W4306971427 hasAuthorship W4306971427A5007891912 @default.
• W4306971427 hasAuthorship W4306971427A5014871823 @default.
• W4306971427 hasAuthorship W4306971427A5016852500 @default.
• W4306971427 hasAuthorship W4306971427A5017336412 @default.
• W4306971427 hasAuthorship W4306971427A5020408757 @default.
• W4306971427 hasAuthorship W4306971427A5020593703 @default.
• W4306971427 hasAuthorship W4306971427A5022657400 @default.
• W4306971427 hasAuthorship W4306971427A5031687017 @default.
• W4306971427 hasAuthorship W4306971427A5035789115 @default.
• W4306971427 hasAuthorship W4306971427A5038061103 @default.
• W4306971427 hasAuthorship W4306971427A5042066240 @default.
• W4306971427 hasAuthorship W4306971427A5044724288 @default.
• W4306971427 hasAuthorship W4306971427A5048944322 @default.
• W4306971427 hasAuthorship W4306971427A5050962544 @default.
• W4306971427 hasAuthorship W4306971427A5069611083 @default.
• W4306971427 hasBestOaLocation W43069714271 @default.
• W4306971427 hasConcept C121608353 @default.
• W4306971427 hasConcept C126322002 @default.
• W4306971427 hasConcept C141071460 @default.
• W4306971427 hasConcept C143998085 @default.
• W4306971427 hasConcept C159110408 @default.
• W4306971427 hasConcept C160798450 @default.
• W4306971427 hasConcept C197934379 @default.
• W4306971427 hasConcept C2777704003 @default.
• W4306971427 hasConcept C2777757722 @default.
• W4306971427 hasConcept C2777793932 @default.
• W4306971427 hasConcept C2779951463 @default.
• W4306971427 hasConcept C2780943399 @default.
• W4306971427 hasConcept C2781467025 @default.
• W4306971427 hasConcept C509974204 @default.
• W4306971427 hasConcept C530470458 @default.
• W4306971427 hasConcept C535046627 @default.
• W4306971427 hasConcept C71924100 @default.
• W4306971427 hasConceptScore W4306971427C121608353 @default.
• W4306971427 hasConceptScore W4306971427C126322002 @default.
• W4306971427 hasConceptScore W4306971427C141071460 @default.
• W4306971427 hasConceptScore W4306971427C143998085 @default.
• W4306971427 hasConceptScore W4306971427C159110408 @default.
• W4306971427 hasConceptScore W4306971427C160798450 @default.
• W4306971427 hasConceptScore W4306971427C197934379 @default.
• W4306971427 hasConceptScore W4306971427C2777704003 @default.

• next